Fidelity Investments
BBC icon

Fidelity Investments’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Fidelity Investments’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12
Closed -$350 – 5379
2024
Q1 		$350 Buy
+12
New +$329 ﹤0.01% 4875
2019
Q1 		– Sell
-1
Closed – – 3601
2018
Q4 		$0 Buy
+1
New +$27 ﹤0.01% 3516

Other funds holding BBC

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Dynamic Wealth Strategies
Dynamic Wealth Strategies Granite Bay, California $188M AUM 12.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Harbour Investments
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Fidelity Investments's BBC Position: Q2 2024 in Review

Fidelity Investments sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2024, closing a stake of 12 shares — an estimated $350 sold.

Fidelity Investments first reported a position in BBC in Q4 2018 and held it in 2 quarters. The position peaked at $350 in Q1 2024. 14 funds tracked by Wall St. Rank hold BBC as of Q2 2024.

  • Fidelity Investments reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2024 after selling out during the quarter.
  • Fidelity Investments sold 12 Virtus Biotech Clinical Trials ETF shares in Q2 2024, an estimated $350.
  • Fidelity Investments first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2018 and held it in 2 quarters.
  • Fidelity Investments's Virtus Biotech Clinical Trials ETF position peaked at $350 in Q1 2024.
  • 14 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2024.

Based on Fidelity Investments's 13F filing for Q2 2024, filed 13 Aug 2024.